Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Purchased by Wedge Capital Management L L P NC

Wedge Capital Management L L P NC boosted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 105,920 shares of the medical equipment provider’s stock after purchasing an additional 1,688 shares during the period. Wedge Capital Management L L P NC owned approximately 0.05% of Zimmer Biomet worth $11,188,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Dunhill Financial LLC increased its holdings in Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 218 shares in the last quarter. Ashton Thomas Securities LLC acquired a new stake in Zimmer Biomet in the 3rd quarter valued at $28,000. Bangor Savings Bank purchased a new position in Zimmer Biomet in the 3rd quarter valued at about $31,000. Brooklyn Investment Group purchased a new position in Zimmer Biomet in the 3rd quarter valued at about $35,000. Finally, Quarry LP purchased a new position in Zimmer Biomet in the 2nd quarter valued at about $53,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Price Performance

NYSE ZBH opened at $109.65 on Friday. Zimmer Biomet Holdings, Inc. has a 12 month low of $100.67 and a 12 month high of $133.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The firm has a market capitalization of $21.83 billion, a PE ratio of 20.85, a P/E/G ratio of 1.79 and a beta of 1.02. The company’s 50 day simple moving average is $107.84 and its 200 day simple moving average is $107.99.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting analysts’ consensus estimates of $1.74. The business had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter last year, the business earned $1.65 earnings per share. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be given a $0.24 dividend. The ex-dividend date is Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.88%. Zimmer Biomet’s dividend payout ratio (DPR) is 18.25%.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ZBH shares. BTIG Research decreased their price objective on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research report on Thursday, October 3rd. Raymond James decreased their price objective on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Wells Fargo & Company upped their price objective on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Finally, Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Thursday, October 31st. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $123.33.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.